Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Inhibiting SLC25A51 for AML

BC Staff
March 26, 2024 7:51 PM UTC

Inhibiting SLC25A51, a mitochondrial NAD+ transporter, could help treat AML by decreasing the oxidative NAD+/NADH ratio, which fuels cancer cell proliferation.  

Bioinformatic analyses of AML patient transcriptomic data identified SLC25A51 mRNA as highly expressed in cancer cells compared with hematopoietic stem cells (HSCs) from healthy patients, and higher tumor expression of SLC25A51 was associated with worse overall survival. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Bristol Myers Squibb Co.

University of Texas at Austin